AKT1 and renal cell carcinoma: PI3K/AKT/mTOR signaling pathway dysregulation is frequently identified in patients with RCC (Han et al., 2017), and inhibitors of mTOR, including everolimus and temsirolimus, have proven efficacious in mRCC (Escudier et al., 2014; Ghidini et al., 2017).